Global pharmaceutical manufacturer Lonza began construction in April of 2016 on a 100,000-sf facility in Pearland, Texas. Featuring a fully segregated fill/finish suite, the project will include eight independent cGMP modular cleanrooms with single-use bioreactors for the production of viral gene and virally modified therapeutics. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. Operations are expected to begin at the site in mid-2017. The architect of record for the facility is Rogue Architects of Fort Worth with CrossPoint Engineering as civil engineer. The project team also includes CRB, Pinchal & Co., Creed Commercial Development, and ARCO Design/Build. Lonza is based in Basel, Switzerland.
| Organization | Project Role |
|---|---|
|
CRB
|
Engineer
|
